Surface lanes with both high HHI concentration and high median price. The pricing-power assets where premium positioning is defensible, not erosion-prone.
Enzalutamide India-into-Turkey clears at $3,851.62/kg median across HHI 9,867 and 6 active exporters. The top three share 99.8% of the lane volume. The corridor is structurally a premium-specialty environment: high price, low competitor count, anchor-buyer relationships. A pricing team running this lane defends with longer contracts, regulatory exclusivity protection, and capacity ring-fence. The companion lane to Singapore (HHI 6,798, 5 exporters, median $33) is the volume-tender counterpart; same molecule, different game.
| # | Lane | Origin | Median | Exporters | HHI |
|---|---|---|---|---|---|
| 1 | Enzalutamide · India → Turkey | IN → TR | 6 exporters | $3,851.62 · HHI 9,867 | NAI |
| 2 | Vortioxetine · India → Brazil | IN → BR | 5 exporters | $3,215.10 · HHI 6,356 | VAI |
| 3 | Linagliptin · India → Philippines | IN → PH | 6 exporters | $1,200.00 · HHI 5,673 | NAI |
| 4 | Olaparib · India → Korea | IN → KR | 5 exporters | $2,400.00 · HHI 7,200 | NAI |
| 5 | Palbociclib · India → Brazil | IN → BR | 6 exporters | $5,800.00 · HHI 5,900 | VAI |
Default: HHI above 5,000 plus median above $500/kg. Configurable. Higher thresholds (HHI 8,000, $1,000 median) surface only the premium-tier; lower thresholds surface emerging premium lanes.
All molecule-origin-destination triples meeting both thresholds, ranked by median price. The top-3 share and exporter count surface alongside each lane.
Citation-anchored brief: the lane list, the HHI trajectory across the trailing 3 years, and a chip for each lane on whether new entrants are arriving (erosion signal).
Premium price holds where concentration holds. The dual filter (HHI above 5,000, median above $500) catches lanes where the premium has a structural reason; not lanes where one shipment happened to clear high.
Each lane carries an HHI trajectory. Lanes where HHI is falling and exporter count is rising are flagged as approaching erosion; the user can act before the median drops.
Same molecule into different destinations often shows a premium lane and a volume-tender lane side by side. The brief surfaces both so the user can think about portfolio allocation by tier.
Trade aggregates refresh weekly. The premium register reruns on every refresh; the brief carries the exact computation timestamp.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Eleven premium-specialty lanes · HHI on the 0-10,000 scale · companion lane comparison where same molecule clears multiple destinations.
The premium register is the pricing-power asset map. PharmaDB joins lane_competitiveness (HHI, exporter count) to molecule_country_flow (lane median), surfaces lanes meeting both thresholds, and overlays an HHI trajectory chip. Refresh cadence is weekly.
High HHI alone can mean a tender market with a low anchor price; that is not a premium lane. High median alone can mean one shipment cleared high without competition; that is not defensible. Both filters together catch the lanes where the premium is structural.
HHI above 5,000 (top 10,000 scale) corresponds to roughly 50% top-3 share or higher; above 8,000 is duopoly territory. The premium register uses 5,000 as the entry threshold; the apex tier uses 8,000.
Same molecule into a tender market (Saudi Arabia, Bangladesh, Philippines large-tender) clears at a different band than into a branded-equivalent market (Turkey, Korea, Brazil specialty). Both surface in the warehouse; the brief shows them side by side so the user can think about the tier strategy.
HHI trajectory across the trailing 3 years. A lane where HHI was 9,500 three years ago and is now 7,200 is flagged as eroding even if it still meets the threshold. The user gets the early warning before the median moves.
Identities are aggregated and anonymised at the threshold required by the trade-data disclaimer. The premium register uses lane aggregates only; never named-counterparty transaction data.
Customs and lane competitiveness aggregates both refresh weekly. The register reruns on every refresh; the catalog row carries the exact timestamp.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.